Opinion | The Promises And Perils of CRISPR
Recently, the US Food and Drug Administration approved two landmark gene therapies, Casgevy and Lyfgenia, marking a landmark in how we treat patients. These therapies are cell-based treatments for sickle cell disease (SCD) in patients aged 12 and older. …